Study examines antibody response to COVID-19 vaccination in patients with kidney failure

Credit: CC0 Public Domain

In a recent study, most patients with kidney failure who were undergoing hemodialysis developed a substantial antibody response following the vaccination with the Pfizer-BioNTech vaccine against COVID-19, but it was significantly lower than that of individuals without kidney disease. The findings will appear in an upcoming issue of CJASN.

Individuals with kidney failure who are receiving have a higher risk of experiencing severe COVDI-19 if they become infected with the virus that causes the disease. Therefore, vaccination may be especially important for these patients; however, they also tend to mount reduced immune responses against infections and vaccinations. To assess their responses to COVID-19 vaccination, a team led by Moshe Shashar MD (Laniado Hospital and Tel-Aviv Medical Center, Israel) compared antibody responses following vaccination with the Pfizer-BioNTech vaccine in 56 patients on maintenance hemodialysis vs. 95 .

All of the healthcare workers developed a positive antibody response to the virus that causes COVID-19, compared with 96% of participants in the dialysis group. The average antibody levels in patients on dialysis were significantly lower than those among healthcare workers. Also, there was a significant inverse correlation of age and antibody levels in both groups.

Although the findings are preliminary and warrant further clarifications and verifications, they suggest that COVD-19 vaccination doses and schedules should be reconsidered for individuals with kidney failure who are on dialysis.

“I believe our findings should encourage patients with treated with dialysis to be vaccinated as soon as vaccination becomes available for them, while we as a care givers should explore ways to enhance its efficacy in our patients,” said Dr. Shashar.

COVID-19 survivors might need just one dose of two-part vaccine

More information:
“Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis,” DOI: 10.2215/CJN.03500321

Study examines antibody response to COVID-19 vaccination in patients with kidney failure (2021, April 6)
retrieved 6 April 2021

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Health News

mRNA vaccine more effective booster to ChAdOx1 nCoV-19

(HealthDay)—Use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is more effective than homologous ChAdOx1 nCoV-19/ChAdOx1 nCoV-19 prime-boost vaccination, according to a study published online Oct. 17 in The Lancet Regional Health: Europe. Peter Nordström, M.D., Ph.D., from Umeå University in Sweden, and colleagues examined the effectiveness of heterologous prime-boost COVID-19 vaccination among individuals in […]

Read More
Health News

Moving monoclonal antibody treatments for COVID from hospital to home

(HealthDay)—Antibody infusions help keep high-risk COVID-19 patients out of the hospital, but getting the therapy can be a challenge. One U.S. health system has found a creative way to address the problem: home infusions administered by paramedics. They delivered antibody infusions to 144 COVID-19 patients in their homes over three months earlier this year. Most—about […]

Read More
Health News

Most kids newly diagnosed with ADHD aren’t getting best care

(HealthDay)—Preschoolers with attention deficit hyperactivity disorder (ADHD) rarely receive the gold-standard treatment recommended by the American Academy of Pediatrics (AAP) for their condition, a new study reports. The AAP recommends a behavioral therapy technique called “parent training in behavior management,” or PTBM, as first-line treatment for ADHD kids ages 4 and 5. But only 1 […]

Read More